We are live on
!
Find out more
PM
Prosight Management Portfolio holdings
AUM
$580M
1-Year Est. Return
29.81%
This Fund
S&P 500
This Quarter
Est. Return
-0.09%
1 Year Est. Return
+29.81%
3 Year Est. Return
+39.55%
5 Year Est. Return
-6.93%
10 Year Est. Return
–
AUM
$136M
AUM Growth
-$23M
(-14%)
Cap. Flow
-$16.5M
Cap. Flow
% of AUM
-12.08%
Top 10 Holdings %
Top 10 Hldgs %
63.07%
Holding
41
New
10
Increased
7
Reduced
14
Closed
10
Avg Time Held Equity + Options
1.1
quarters
Top 10 Avg Time Held Equity + Options
0.6
quarters
Top 20 Avg Time Held Equity + Options
1.2
quarters
Avg Time Held Equity only
1.1
quarters
Top 10 Avg Time Held Equity only
0.6
quarters
Top 20 Avg Time Held Equity only
1.2
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cigna
CI
|
+$7.82M |
| 2 |
ATHN
Athenahealth, Inc.
ATHN
|
+$6.11M |
| 3 |
Indaptus Therapeutics
INDP
|
+$5.57M |
| 4 |
Neurogene
NGNE
|
+$5.22M |
| 5 |
Kura Oncology
KURA
|
+$4.88M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SHPG
Shire pic
SHPG
|
+$18.4M |
| 2 |
Sabra Healthcare REIT
SBRA
|
+$9.4M |
| 3 |
AFAM
Almost Family Inc
AFAM
|
+$7.56M |
| 4 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
+$6.54M |
| 5 |
DexCom
DXCM
|
+$4.82M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 93.5% |
| 2 | Industrials | 4.81% |
| 3 | Real Estate | 1.58% |
| 4 | Miscellaneous | 0.12% |
| 5 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Cigna
CI
$74.7B
| $13.2M | 9.64% |
77,400
+45,200
| +140% | +$7.82M |
2018 Q1
1 quarter
|
|
2
MacroGenics
MGNX
$218M
| $12.8M | 9.36% |
618,515
+173,515
| +39% | +$3.91M |
2017 Q4
2 quarters
|
|
|
AGN
3
DELISTED
Allergan plc
AGN
| $12M | 8.76% |
71,700
-23,100
| -24% | -$3.71M |
2017 Q4
2 quarters
|
|
|
TLGT
4
DELISTED
Teligent, Inc
TLGT
| $11.5M | 8.43% |
332,500
+85,244
| +34% | +$2.68M |
2018 Q1
1 quarter
|
|
5
Palvella Therapeutics
PVLA
$1.85B
| $6.89M | 5.05% |
17,000
+9,953
| +141% | +$4.74M |
2018 Q1
1 quarter
|
|
|
ATHN
6
DELISTED
Athenahealth, Inc.
ATHN
| $6.55M | 4.81% |
+41,193
| New | +$6.11M |
2018 Q2
0 quarters
|
|
|
ARNA
7
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $6.08M | 4.46% |
139,528
+19,128
| +16% | +$822K |
2018 Q1
1 quarter
|
|
8
DELISTED
Cidara Therapeutics
CDTX
| $6.03M | 4.42% |
57,935
-1,383
| -2% | -$131K |
2017 Q4
2 quarters
|
|
9
Iovance Biotherapeutics
IOVA
$6.57B
| $5.63M | 4.13% |
439,900
+230,058
| +110% | +$3.36M |
2017 Q4
2 quarters
|
|
10
BioMarin Pharmaceuticals
BMRN
$10.5B
| $5.45M | 4% |
57,900
-5,500
| -9% | -$482K |
2018 Q1
1 quarter
|
|
|
SHPG
11
DELISTED
Shire pic
SHPG
| $5.4M | 3.96% |
32,000
-114,114
| -78% | -$18.4M |
2018 Q1
1 quarter
|
|
|
EIGR
12
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $5.35M | 3.92% |
14,614
-3,081
| -17% | -$1.1M |
2017 Q4
2 quarters
|
|
|
SRRA
13
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $5.35M | 3.92% |
45,164
-18,299
| -29% | -$1.84M |
2018 Q1
1 quarter
|
|
|
14
Kura Oncology
KURA
$874M
| $5.24M | 3.84% |
+287,887
| New | +$4.88M |
2018 Q2
0 quarters
|
|
|
15
Indaptus Therapeutics
INDP
$318M
| $4.95M | 3.63% |
+502
| New | +$5.57M |
2018 Q2
0 quarters
|
|
|
AKAO
16
DELISTED
Achaogen Inc
AKAO
| $3.25M | 2.38% |
375,000
-286,054
| -43% | -$3.48M |
2017 Q4
2 quarters
|
|
17
Viatris
VTRS
$19.8B
| $2.92M | 2.14% |
+80,800
| New | +$3.17M |
2018 Q2
0 quarters
|
|
|
RETA
18
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $2.91M | 2.13% |
83,094
-214,656
| -72% | -$6.54M |
2017 Q4
2 quarters
|
|
19
Assembly Biosciences
ASMB
$414M
| $2.56M | 1.88% |
+5,442
| New | +$2.88M |
2018 Q2
0 quarters
|
|
|
20
Sabra Healthcare REIT
SBRA
$4.93B
| $2.15M | 1.58% |
98,906
-481,094
| -83% | -$9.4M |
2017 Q4
2 quarters
|
|
21
DELISTED
Esperion Therapeutics
ESPR
| $1.91M | 1.4% |
+48,800
| New | +$2.47M |
2018 Q2
0 quarters
|
|
|
PRTK
22
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
| $1.48M | 1.08% |
144,752
-3,930
| -3% | -$44.5K |
2017 Q4
2 quarters
|
|
|
NBRV
23
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
| $1.47M | 1.08% |
1,686
+715
| +74% | +$819K |
2017 Q4
2 quarters
|
|
24
Centene
CNC
$34B
| $1.34M | 0.98% |
21,750
-25,000
| -53% | -$1.44M |
2017 Q4
2 quarters
|
|
|
25
Neurogene
NGNE
$431M
| $1.06M | 0.78% |
+20,045
| New | +$5.22M |
2018 Q2
0 quarters
|
|
Similar funds
SC
CCWM
CMA
RIS
MFS
GFI
PWM
CA
Prosight Management's Q2 2018 Portfolio in Review
As of Q2 2018, Prosight Management held 41 positions worth $136M, down 14% from $159M the previous quarter. Its ten largest holdings account for 63% of the portfolio.
Prosight Management withdrew a net $16.5M in Q2 2018, closing 10 positions and reducing 14 holdings. Its most notable exit was Almost Family Inc, an estimated $7.56M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 85% a quarter earlier, followed by Industrials and Real Estate.
Against the trend, Prosight Management opened a new position in Athenahealth, Inc. worth $6.55M.
- Prosight Management's largest Q2 2018 buy was Athenahealth, Inc.: 41,193 shares worth $6.55M.
- Prosight Management added most to Cigna in Q2 2018, an estimated $7.82M increase.
- Prosight Management's biggest Q2 2018 reduction was Shire pic, cutting an estimated $18.4M.
- Prosight Management fully exited Almost Family Inc in Q2 2018, selling an estimated $7.56M.
- Prosight Management's ten largest holdings make up 63% of its $136M portfolio in Q2 2018.
- Prosight Management opened 10 new positions and closed 10 in Q2 2018.
- Prosight Management's portfolio value fell 14% quarter-over-quarter to $136M.
Based on Prosight Management's 13F filing for Q2 2018, filed 14 Aug 2018.